Self-administration of research peptides carries inherent risks including contamination, incorrect dosing, and unknown long-term effects
These include: Lifestyle interventions (dietary advice, physical activity programmes) Licensed pharmacotherapy such as orlistat, or GLP-1 receptor agonists including semaglutide 2.4 mg (Wegovy, NICE TA875) or tirzepatide (Zepbound) where clinically indicated and available Referral to tier 3 or tier 4 weight management services , including bariatric surgery assessment where appropriate Information on NHS weight management services and eligibility for licensed treatments is available via the NHS website and NICE guidance
Insider Tip: BPC-157 should not be used by people with diagnosed or suspected cancer, as its potential to promote new blood vessel formation could cause cancer to grow or spread.19 Whos a candidate for BPC-157 peptide therapy
Users who have achieved significant results may choose to continue at a maintenance dose, take a break and reassess, or adjust their protocol in consultation with a healthcare provider
The commenter further noted that first-year costs associated with these activities range between $20,000 and $50,000 with additional annual expenses incurred thereafter
